Olema Pharmaceuticals, Inc. Logo

Olema Pharmaceuticals, Inc.

A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.

OLMA | US

Overview

Corporate Details

ISIN(s):
US68062P1066
LEI:
Country:
United States of America
Address:
780 BRANNAN STREET, 94103 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Operating as Olema Oncology, the company is dedicated to transforming the standard of care, with a primary focus on breast cancer. Its lead product candidate, palazestrant (OP-1250), is a novel, investigational agent being developed for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Olema's mission is to develop more effective and tolerable medicines to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Olema Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Olema Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Olema Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PALVELLA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing topical therapies for rare genetic skin diseases.
United States of America
PVLA
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea
222110
Pasithea Therapeutics Corp. Logo
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America
KTTA
Pelthos Therapeutics Inc. Logo
Biopharma with an approved gel for molluscum, advancing a nitric oxide-based pipeline.
United States of America
PTHS
Pentixapharm Holding AG Logo
Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.
Germany
PTP
PeopleBio, Inc. Logo
Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.
South Korea
304840
PEPTONIC Medical AB Logo
Develops clinically proven self-care products for women's intimate health.
Sweden
PMED
Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.
South Korea
087010
PERRIGO Co plc Logo
World's largest manufacturer of store-brand OTC consumer health products.
United States of America
PRGO
Perseus Proteomics Inc. Logo
Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.
Japan
4882

Talk to a Data Expert

Have a question? We'll get back to you promptly.